Bright Minds Biosciences Inc. – NASDAQ:DRUG

Add to watchlist

$43

+3.11

+7.82%

Market closed

Open in about 3 hours

+4043.38%

month

+4043.38%

quarter

+2506.54%

year

Market Cap	274.25M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-1.49

Revenue	N/A
EBITDA	-5.51M
Income	-5.69M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Bright Minds Biosciences Inc. (NASDAQ:DRUG): Profit margin
Mar 2023	0	-2.13M
Jun 2023	0	-1.45M
Sep 2023	0	-1.52M
Mar 2024	0	-574.14K

Bright Minds Biosciences Inc. (NASDAQ:DRUG): Debt to assets
Mar 2023	9987002	1.04M	10.42%
Jun 2023	8460529	734.81K	8.69%
Sep 2023	6879072	280.85K	4.08%
Mar 2024	6531186	845.78K	12.95%

Bright Minds Biosciences Inc. (NASDAQ:DRUG): Cash Flow
Mar 2023	-1.51M	-21.49K
Jun 2023	-1.65M	-21.48K
Sep 2023	-1.19M	-21.64K
Mar 2024	-805.08K	-21.95K

Bright Minds Biosciences
Hedge Funds Holdings Q1 2023

4.71% +1.41%

of DRUG is owned by hedge funds

8 +0

hedge funds hold DRUG stock

581.55K +173.62K

shares is hold by hedge funds

DRUG hedge funds holdings changes

Bright Minds Biosciences
Executives

Insider	Age	Compensation
Dr. Alan Kozikowski Ph.D. (1950) Chief Scientific Officer & Director	75	$210,450
Dr. Revati Shreeniwas FCCP, M.D., Ph.D. (1961) Chief Medical Officer	64	$192,660
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA (1978) Chief Financial Officer	47	$68,330

Bright Minds Biosciences
Latest News

Monday, 9 December 2024
07:33	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER	prnewswire.com
Wednesday, 13 November 2024
12:59	Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month	fool.com
Wednesday, 6 November 2024
17:21	CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY	prnewswire.com
Monday, 4 November 2024
14:41	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement	globenewswire.com
Wednesday, 30 October 2024
01:07	Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential	seekingalpha.com
Monday, 28 October 2024
08:21	PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update	businesswire.com
Monday, 21 October 2024
08:30	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data	globenewswire.com
Saturday, 19 October 2024
13:11	Monster insider trading alert for this penny stock that rallied $3,700% in a week	finbold.com
Friday, 18 October 2024
06:50	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement	globenewswire.com
Wednesday, 16 October 2024
10:45	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models	globenewswire.com
09:05	Why did this penny stock skyrocket 1,500% in a day	finbold.com
08:46	Bright Minds Biosciences Stock Surges Almost 1,500%	marketbeat.com
08:04	Canadian psychedelics company Bright Minds shares rise 1,446% in one day	proactiveinvestors.co.uk
Tuesday, 15 October 2024
21:09	Bright Minds is Unaware of Any Material Changes	newsfilecorp.com
Thursday, 3 October 2024
09:00	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events	globenewswire.com
Thursday, 19 September 2024
10:00	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th	globenewswire.com
Thursday, 12 September 2024
08:00	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy	prnewswire.com
Tuesday, 25 June 2024
08:05	HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)	prnewswire.com
Monday, 24 June 2024
07:00	HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY	prnewswire.com
Tuesday, 11 June 2024
08:10	ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY	globenewswire.com
Tuesday, 8 August 2023
06:50	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	globenewswire.com
Thursday, 20 July 2023
06:50	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	globenewswire.com
Wednesday, 12 July 2023
10:33	CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)	newsfilecorp.com
Tuesday, 11 July 2023
06:50	Bright Minds Announces Effective Date of Share Consolidation	globenewswire.com
Wednesday, 19 April 2023
15:29	Penny Stocks To Buy? 10 Under $1 To Watch This Week	PennyStocks
Monday, 10 April 2023
06:50	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research	GlobeNewsWire
Tuesday, 18 October 2022
14:40	What Is Going on With Bright Minds (DRUG) Stock Today?	InvestorPlace
Sunday, 18 September 2022
11:30	Making Money With Penny Stocks When the Market Crashes	PennyStocks
Sunday, 4 September 2022
11:30	Which Strategies Are You Using With Penny Stocks in September?	PennyStocks
Friday, 2 September 2022
12:28	Best Penny Stocks To Buy Now? 4 To Watch This Month	PennyStocks

Frequently Asked Questions (FAQ)

What's the price of Bright Minds Biosciences stock today?

One share of Bright Minds Biosciences stock can currently be purchased for approximately $43.
When is Bright Minds Biosciences's next earnings date?

Unfortunately, Bright Minds Biosciences's (DRUG) next earnings date is currently unknown.
Does Bright Minds Biosciences pay dividends?

No, Bright Minds Biosciences does not pay dividends.
How much money does Bright Minds Biosciences make?

Bright Minds Biosciences has a market capitalization of 274.25M.
What is Bright Minds Biosciences's stock symbol?

Bright Minds Biosciences Inc. is traded on the NASDAQ under the ticker symbol "DRUG".
What is Bright Minds Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Bright Minds Biosciences?

Shares of Bright Minds Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Bright Minds Biosciences's key executives?
Bright Minds Biosciences's management team includes the following people:
- Dr. Alan Kozikowski Ph.D. Chief Scientific Officer & Director(age: 75, pay: $210,450)
- Dr. Revati Shreeniwas FCCP, M.D., Ph.D. Chief Medical Officer(age: 64, pay: $192,660)
- Mr. Ryan E. S. K. Cheung B.Com., CA, CPA Chief Financial Officer(age: 47, pay: $68,330)
When Bright Minds Biosciences went public?

Bright Minds Biosciences Inc. is publicly traded company for more then 4 years since IPO on 22 Mar 2021.
What is Bright Minds Biosciences's official website?

The official website for Bright Minds Biosciences is brightmindsbio.com.
Where are Bright Minds Biosciences's headquarters?

Bright Minds Biosciences is headquartered at 1500 – 1055 West Georgia Street, Vancouver, BC.
How can i contact Bright Minds Biosciences?

Bright Minds Biosciences's mailing address is 1500 – 1055 West Georgia Street, Vancouver, BC and company can be reached via phone at +64 7 407 2515.

Bright Minds Biosciences Inc.

brightmindsbio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

+64 7 407 2515

1500 – 1055 West Georgia Street
Vancouver, BC V6E 4N7

CIK: 0001827401
ISIN: CA10919W4056
CUSIP: 10919W108